{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:19:44Z","timestamp":1790709584051,"version":"4.1.0"},"reference-count":129,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"crossref","award":["LINEA 1\/13_26"],"award-info":[{"award-number":["LINEA 1\/13_26"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]},{"award":["LINEA 1\/13_26"],"award-info":[{"award-number":["LINEA 1\/13_26"]}],"id":[{"id":"https:\/\/ror.org\/00789fa95","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The advent of novel Human Epidermal growth factor Receptor 2 (HER2)-targeted therapies and tyrosine kinase inhibitors (TKIs) has significantly improved outcomes in HER2-positive malignancies, particularly breast cancer. However, these agents carry a growing burden of cardiovascular adverse events, representing a critical concern in modern oncology. This narrative review explores the evolving landscape of cardiovascular toxicity associated with these therapeutic classes, integrating mechanistic insights with real-world clinical data. HER2-targeting monoclonal antibodies and antibody\u2013drug conjugates exert off-target effects on cardiomyocytes via HER2 pathway inhibition, leading to reversible or irreversible myocardial dysfunction. In parallel, small-molecule TKIs, especially those targeting multiple kinases, have been associated with hypertension, arrhythmia, QT prolongation, and heart failure, through mechanisms such as mitochondrial dysfunction, endothelial damage, and disruption of cardioprotective signaling. We summarize clinical evidence elucidating the molecular basis of these toxicities and critically review clinical trials and post-marketing data highlighting their incidence and management. The review emphasizes the heterogeneity of cardiotoxicity profiles across different agents, underscoring the need for individualized cardiovascular risk stratification and monitoring. Finally, we address the emerging role of cardio-oncology in bridging oncologic efficacy with cardiac safety, advocating for multidisciplinary approaches, biomarker-guided surveillance, and standardized definitions of cardiotoxicity. As precision oncology advances, a parallel refinement in cardiotoxicity prediction and prevention is imperative to optimize patient outcomes.<\/jats:p>","DOI":"10.3390\/ph19060833","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:36:56Z","timestamp":1779892616000},"page":"833","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0727-2717","authenticated-orcid":false,"given":"Amro","family":"Abu Suleiman","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, York and Scarborough Teaching Hospitals NHS Trust, York YO31 8HE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Quagliariello","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-4121","authenticated-orcid":false,"given":"Luigi","family":"Spadafora","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8457-7822","authenticated-orcid":false,"given":"Federico","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy"},{"name":"Division of Cardiology, Sant\u2019Andrea University Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3704-0092","authenticated-orcid":false,"given":"Nicola","family":"Maurea","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB Signalling Network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","article-title":"HER2-Targeted Therapies beyond Breast Cancer\u2014An Update","volume":"21","author":"Yoon","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","article-title":"Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, with or without Trastuzumab as Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: NSABP B-31","volume":"23","author":"Yothers","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10549-019-05453-z","article-title":"A Pooled Analysis of the Cardiac Events in the Trastuzumab Adjuvant Trials","volume":"179","author":"Ponde","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14740338.2017.1351541","article-title":"Breast Cancer Treatment-Induced Cardiotoxicity","volume":"16","author":"Martel","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/378394a0","article-title":"Requirement for Neuregulin Receptor erbB2 in Neural and Cardiac Development","volume":"378","author":"Lee","year":"1995","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 Is Essential in the Prevention of Dilated Cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1073\/pnas.122249299","article-title":"Conditional Mutation of the ErbB2 (HER2) Receptor in Cardiomyocytes Leads to Dilated Cardiomyopathy","volume":"99","author":"Ozcelik","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"10261","DOI":"10.1074\/jbc.273.17.10261","article-title":"Neuregulins Promote Survival and Growth of Cardiac Myocytes. Persistence of ErbB2 and ErbB4 Expression in Neonatal and Adult Ventricular Myocytes","volume":"273","author":"Zhao","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-Oncology Services: Rationale, Organization, and Implementation","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jcmg.2020.09.039","article-title":"Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison with Echocardiography","volume":"14","author":"Houbois","year":"2021","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of Cardiac Disease in Cancer Patients throughout Oncological Treatment: ESMO Consensus Recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ejhf.1292","article-title":"Activity and Outcomes of a Cardio-Oncology Service in the United Kingdom\u2014A Five-Year Experience","volume":"20","author":"Pareek","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3747\/co.26.4509","article-title":"Clinical Experience of Patients Referred to a Multidisciplinary Cardio-Oncology Clinic: An Observational Cohort Study","volume":"26","author":"Kappel","year":"2019","journal-title":"Curr. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Canale, M.L., Turazza, F., Lestuzzi, C., Parrini, I., Camerini, A., Russo, G., Colivicchi, F., Gabrielli, D., Gulizia, M.M., and Oliva, S. (2021). Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.677544"},{"key":"ref_19","first-page":"14","article-title":"Early Access to a Cardio-Oncology Clinic in an Australian Context: A Qualitative Exploration of Patient Experiences","volume":"8","author":"White","year":"2022","journal-title":"Cardiooncology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijcard.2022.06.063","article-title":"Predictability of Cardiotoxicity: Experience of a Belgian Cardio-Oncology Clinic","volume":"363","author":"Jacobs","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijcard.2021.11.059","article-title":"Baseline Cardio-Oncologic Risk Assessment in Breast Cancer Women and Occurrence of Cardiovascular Events: The HFA\/ICOS Risk Tool in Real-World Practice","volume":"349","author":"Tini","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103816","DOI":"10.1016\/j.clon.2025.103816","article-title":"Implementation of a Cardio-Oncology Service for Management of Breast Cancer Patients on Anti-HER2 Treatment","volume":"40","author":"Boardman","year":"2025","journal-title":"Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"852748","DOI":"10.1155\/2014\/852748","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol. Biol. Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.107.690487","article-title":"Role of Neuregulin-1\/ErbB Signaling in Cardiovascular Physiology and Disease","volume":"116","author":"Lemmens","year":"2007","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2004.08.066","article-title":"Inhibition of ErbB2 Causes Mitochondrial Dysfunction in Cardiomyocytes: Implications for Herceptin-Induced Cardiomyopathy","volume":"44","author":"Grazette","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"H2139","DOI":"10.1152\/ajpheart.00063.2012","article-title":"The Role of Neuregulin\/ErbB2\/ErbB4 Signaling in the Heart with Special Focus on Effects on Cardiomyocyte Proliferation","volume":"302","author":"Wadugu","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.cell.2009.04.060","article-title":"Neuregulin1\/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury","volume":"138","author":"Bersell","year":"2009","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0014-4827(02)00101-5","article-title":"The Deaf and the Dumb: The Biology of ErbB-2 and ErbB-3","volume":"284","author":"Citri","year":"2003","journal-title":"Exp. Cell Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"12055","DOI":"10.1074\/jbc.M211948200","article-title":"Selective Formation of ErbB-2\/ErbB-3 Heterodimers Depends on the ErbB-3 Affinity of Epidermal Growth Factor-like Ligands","volume":"278","author":"Stortelers","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER Family of Protein-Tyrosine Kinases and Cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.ajpath.2019.06.008","article-title":"Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia","volume":"189","author":"Black","year":"2019","journal-title":"Am. J. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse Cardiac Effects of Cancer Therapies: Cardiotoxicity and Arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","article-title":"Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes","volume":"15","author":"Mohan","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_34","first-page":"70","article-title":"Trastuzumab-Induced Cardiac Dysfunction: A \u201cDual-Hit\u201d","volume":"16","author":"Zeglinski","year":"2011","journal-title":"Exp. Clin. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer","volume":"377","author":"Minckwitz","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1074\/jbc.M804570200","article-title":"Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-Dependent Pathways","volume":"284","author":"Gordon","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.7150\/ijbs.110580","article-title":"Exogenous SPD Inhibits Trastuzumab-Mediated Cardiomyocyte Pyroptosis through SIRT3-Regulated Mitochondrial Quality Control","volume":"21","author":"Yu","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41392-024-01839-8","article-title":"Mitochondrial Dysfunction: Mechanisms and Advances in Therapy","volume":"9","author":"Zong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody Drug Conjugate: The \u201cBiological Missile\u201d for Targeted Cancer Therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2019.11.023","article-title":"Trastuzumab Emtansine (T-DM1)-Associated Cardiotoxicity: Pooled Analysis in Advanced HER2-Positive Breast Cancer","volume":"126","author":"Ameye","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1158\/1078-0432.CCR-11-0762","article-title":"Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s10120-021-01196-3","article-title":"Discovery and Development of Trastuzumab Deruxtecan and Safety Management for Patients with HER2-Positive Gastric Cancer","volume":"24","author":"Shitara","year":"2021","journal-title":"Gastric Cancer"},{"key":"ref_43","first-page":"55","article-title":"Mechanisms Contributing to Ado-Trastuzumab Emtansine-Induced Toxicities: A Gateway to Better Understanding of ADC-Associated Toxicities","volume":"4","author":"Endo","year":"2021","journal-title":"Antib. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Morelli, M.B., Bongiovanni, C., Da Pra, S., Miano, C., Sacchi, F., Lauriola, M., and D\u2019Uva, G. (2022). Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.847012"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Cardinale, D., Iacopo, F., and Cipolla, C.M. (2020). Cardiotoxicity of Anthracyclines. Front. Cardiovasc. Med., 7.","DOI":"10.3389\/fcvm.2020.00026"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined with Docetaxel in Patients with Human Epidermal Growth Factor Receptor 2\u2013Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group","volume":"23","author":"Marty","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10549-006-9306-9","article-title":"Randomized Phase II Trial of Weekly Paclitaxel Alone versus Trastuzumab plus Weekly Paclitaxel as First-Line Therapy of Patients with Her-2 Positive Advanced Breast Cancer","volume":"101","author":"Gasparini","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1158\/1078-0432.CCR-06-1345","article-title":"Neoadjuvant Therapy with Paclitaxel Followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2\u2013Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen","volume":"13","author":"Buzdar","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","article-title":"Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women with Human Epidermal Growth Factor Receptor 2\u2013Positive, Hormone Receptor\u2013Positive Metastatic Breast Cancer: Results from the Randomized Phase III TAnDEM Study","volume":"27","author":"Kaufman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1200\/JCO.2009.23.0946","article-title":"Trastuzumab for Patients with Axillary-Node\u2013Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial","volume":"27","author":"Spielmann","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","article-title":"Neoadjuvant Treatment with Trastuzumab in HER2-Positive Breast Cancer: Results from the GeparQuattro Study","volume":"28","author":"Untch","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","article-title":"Neoadjuvant Chemotherapy with Trastuzumab Followed by Adjuvant Trastuzumab versus Neoadjuvant Chemotherapy Alone, in Patients with HER2-Positive Locally Advanced Breast Cancer (the NOAH Trial): A Randomised Controlled Superiority Trial with a Parallel HER2-Negative Cohort","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant Trastuzumab in HER2-Positive Breast Cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(13)70502-3","article-title":"Fluorouracil, Epirubicin, and Cyclophosphamide (FEC-75) Followed by Paclitaxel plus Trastuzumab versus Paclitaxel plus Trastuzumab Followed by FEC-75 plus Trastuzumab as Neoadjuvant Treatment for Patients with HER2-Positive Breast Cancer (Z1041): A Randomised, Controlled, Phase 3 Trial","volume":"14","author":"Buzdar","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","article-title":"Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) with ACP Plus Trastuzumab As Adjuvant Therapy for Patients with Node-Positive, Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancer","volume":"30","author":"Romond","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.ejca.2011.06.021","article-title":"Trastuzumab beyond Progression: Overall Survival Analysis of the GBG 26\/BIG 3-05 Phase III Study in HER2-Positive Breast Cancer","volume":"47","author":"Minckwitz","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","article-title":"Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)","volume":"32","author":"Procter","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ejca.2015.05.028","article-title":"Cardiac Toxicity Events in the PHARE Trial, an Adjuvant Trastuzumab Randomised Phase III Study","volume":"51","author":"Pivot","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","article-title":"Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial","volume":"34","author":"Advani","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1634\/theoncologist.2012-0448","article-title":"Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients with HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study","volume":"18","author":"Swain","year":"2013","journal-title":"Oncologist"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clbc.2019.02.008","article-title":"Results from the First Multicenter, Open-Label, Phase IIIb Study Investigating the Combination of Pertuzumab with Subcutaneous Trastuzumab and a Taxane in Patients with HER2-Positive Metastatic Breast Cancer (SAPPHIRE)","volume":"19","author":"Woodward","year":"2019","journal-title":"Clin. Breast Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10549-020-05728-w","article-title":"Pertuzumab, Trastuzumab, and Docetaxel for Chinese Patients with Previously Untreated HER2-Positive Locally Recurrent or Metastatic Breast Cancer (PUFFIN): A Phase III, Randomized, Double-Blind, Placebo-Controlled Study","volume":"182","author":"Xu","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.annonc.2021.06.024","article-title":"Final Results from the PERUSE Study of First-Line Pertuzumab plus Trastuzumab plus a Taxane for HER2-Positive Locally Recurrent or Metastatic Breast Cancer, with a Multivariable Approach to Guide Prognostication","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10549-021-06145-3","article-title":"Subcutaneous Trastuzumab with Pertuzumab and Docetaxel in HER2-Positive Metastatic Breast Cancer: Final Analysis of MetaPHER, a Phase IIIb Single-Arm Safety Study","volume":"187","author":"Kuemmel","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"O\u2019Shaughnessy, J., Sousa, S., Cruz, J., Fallowfield, D.L., Auvinen, P., Pulido, C., Cvetanovic, A., Wilks, S., Ribeiro, L., and Burotto, M. (2025). Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study. Clin. Breast Cancer, 25.","DOI":"10.1016\/j.clbc.2025.04.016"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab Emtansine versus Treatment of Physician\u2019s Choice in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer (TH3RESA): Final Overall Survival Results from a Randomised Open-Label Phase 3 Trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2018.12.022","article-title":"Safety of Trastuzumab Emtansine (T-DM1) in Patients with HER2-Positive Advanced Breast Cancer: Primary Results from the KAMILLA Study Cohort 1","volume":"109","author":"Montemurro","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1002\/cncr.32392","article-title":"Trastuzumab Emtansine with or without Pertuzumab versus Trastuzumab with Taxane for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results from MARIANNE","volume":"125","author":"Perez","year":"2019","journal-title":"Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non\u2013Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab Deruxtecan versus Treatment of Physician\u2019s Choice in Patients with HER2-Positive Metastatic Breast Cancer (DESTINY-Breast02): A Randomised, Open-Label, Multicentre, Phase 3 Trial","volume":"401","author":"Kim","year":"2023","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non\u2013Small-Cell Lung Cancer: Primary Results from the Randomized, Phase II DESTINY-Lung02 Trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results from the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer: Long-Term Survival Analysis of the DESTINY-Breast03 Trial","volume":"30","author":"Hurvitz","year":"2024","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab Deruxtecan in Patients with HER2-Positive Advanced Colorectal Cancer (DESTINY-CRC02): Primary Results from a Multicentre, Randomised, Phase 2 Trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Seth, L., Bhave, A., Kollapaneni, S., Shah, V., Nahle, T., Blaes, A., Dent, S., Hurvitz, S.A., and Guha, A. (2025). Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis. JAMA Netw. Open, 8.","DOI":"10.1001\/jamanetworkopen.2025.40336"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective Evaluation of the Cardiac Safety of HER2-Targeted Therapies in Patients with HER2-Positive Breast Cancer and Compromised Heart Function: The SAFE-HEaRt Study","volume":"175","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of Heart Failure in Breast Cancer Patients after Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study","volume":"104","author":"Bowles","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10549-018-5058-6","article-title":"A Real-World Study of Cardiac Events in >3700 Patients with HER2-Positive Early Breast Cancer Treated with Trastuzumab: Final Analysis of the OHERA Study","volume":"174","author":"Lidbrink","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","article-title":"Safety of Continuing Trastuzumab Despite Mild Cardio-Toxicity: A Phase I Trial","volume":"1","author":"Leong","year":"2019","journal-title":"JACC CardioOncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jchf.2018.09.001","article-title":"Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab","volume":"7","author":"Banke","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","article-title":"Anti-Tumor Activity of GW572016: A Dual Tyrosine Kinase Inhibitor Blocks EGF Activation of EGFR\/erbB2 and Downstream Erk1\/2 and AKT Pathways","volume":"21","author":"Xia","year":"2002","journal-title":"Oncogene"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/0008-5472.CAN-03-2868","article-title":"Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase","volume":"64","author":"Rabindran","year":"2004","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","article-title":"Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models","volume":"19","author":"Kulukian","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s13402-025-01107-z","article-title":"Pyrotinib Inhibits the Tumorigenicity of HER2-Positive Non-Small Cell Lung Cancer by Inducing ARIH1\/Ubiquitin\/Lysosome-Dependent Degradation of HER2","volume":"48","author":"Li","year":"2025","journal-title":"Cell Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11886-023-01845-2","article-title":"Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors","volume":"25","author":"Sayegh","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse Effects of Tyrosine Kinase Inhibitors in Cancer Therapy: Pathophysiology, Mechanisms and Clinical Management","volume":"8","author":"Sharma","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Chung, R., Tyebally, S., Chen, D., Kapil, V., Walker, J.M., Addison, D., Ismail-Khan, R., Guha, A., Ghosh, A.K., and Chung, R. (2020). Hypertensive Cardiotoxicity in Cancer Treatment\u2014Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies\u2014Epidemiology, Incidence, and Pathophysiology. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103346"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/j.jacc.2021.04.009","article-title":"Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review","volume":"77","author":"Rao","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","article-title":"Pyrotinib plus Capecitabine versus Lapatinib plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer (PHOEBE): A Multicentre, Open-Label, Randomised, Controlled, Phase 3 Trial","volume":"22","author":"Xu","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","article-title":"Neratinib after Trastuzumab-Based Adjuvant Therapy in Patients with HER2-Positive Breast Cancer (ExteNET): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"17","author":"Chan","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1158\/0008-5472.CAN-08-0499","article-title":"Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2","volume":"68","author":"Dai","year":"2008","journal-title":"Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s10549-017-4460-9","article-title":"Cardiac Toxicities of Lapatinib in Patients with Breast Cancer and Other HER2-Positive Cancers: A Meta-Analysis","volume":"166","author":"Choi","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Porta-S\u00e1nchez, A., Gilbert, C., Spears, D., Amir, E., Chan, J., Nanthakumar, K., and Thavendiranathan, P. (2017). Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J. Am. Heart Assoc., 6.","DOI":"10.1161\/JAHA.117.007724"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1634\/theoncologist.12-7-756","article-title":"Lapatinib-Associated Toxicity and Practical Management Recommendations","volume":"12","author":"Moy","year":"2007","journal-title":"Oncologist"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","article-title":"Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13643-022-02134-9","article-title":"Lapatinib and Lapatinib plus Trastuzumab Therapy versus Trastuzumab Therapy for HER2 Positive Breast Cancer Patients: An Updated Systematic Review and Meta-Analysis","volume":"11","author":"Yuan","year":"2022","journal-title":"Syst. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00280-019-03880-9","article-title":"The Effects of Lapatinib on Cardiac Repolarization: Results from a Placebo Controlled, Single Sequence, Crossover Study in Patients with Advanced Solid Tumors","volume":"84","author":"Coker","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated with \u22652 HER2-Directed Regimens: Phase III NALA Trial","volume":"38","author":"Saura","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after Trastuzumab-Based Adjuvant Therapy in HER2-Positive Breast Cancer (ExteNET): 5-Year Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2015.63.0343","article-title":"Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases","volume":"34","author":"Freedman","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER Kinase Inhibition in Patients with HER2- and HER3-Mutant Cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","article-title":"Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)","volume":"23","author":"Moulder","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.clon.2020.06.003","article-title":"Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): A Phase II Randomised Trial","volume":"32","author":"Seligmann","year":"2020","journal-title":"Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"742","DOI":"10.21037\/gs-22-161","article-title":"Cardiotoxicity Monitoring of Pyrotinib in Combination with Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in HER2-Positive Breast Cancer: A Single-Armed Clinical Trial","volume":"11","author":"Wang","year":"2022","journal-title":"Gland. Surg."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Hu, Z.-Y., Yan, M., Xiong, H., Ran, L., Zhong, J., Luo, T., Sun, T., Xie, N., Liu, L., and Yang, X. (2023). Pyrotinib in Combination with Letrozole for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer (PLEHERM): A Multicenter, Single-Arm, Phase II Trial. BMC Med., 21.","DOI":"10.1186\/s12916-023-02943-2"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"102837","DOI":"10.1016\/j.eclinm.2024.102837","article-title":"Pyrotinib plus Capecitabine for Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases (PERMEATE Trial): Overall Survival Results from a Multicenter, Single-Arm, Two-Cohort, Phase 2 Trial","volume":"76","author":"Yan","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Huang, J., Sun, S., Tan, Q., Zheng, F., Zhou, D., Man, X., Hu, Y., Li, W., Song, L., and Zhang, B. (2024). Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study. Clin. Breast Cancer, 24.","DOI":"10.1016\/j.clbc.2024.04.001"},{"key":"ref_120","first-page":"9","article-title":"Cardiotoxicity Report of Letrozole Combined with Pyrotinib as First-Line Treatment in HR+\/HER2+ Patients and New Findings on Lipid Monitoring as Predictive Markers of Efficacy: An Analysis from the PLEHERM Study","volume":"2","author":"Liu","year":"2025","journal-title":"J. Cardio-Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Zhang, Q., He, P., Tian, T., Yan, X., Huang, J., Zhang, Z., Zheng, H., Zhong, X., and Luo, T. (2023). Real-World Efficacy and Safety of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer: A Prospective Real-World Study. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1100556"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Chai, Y., Jiang, M., Wang, Y., Liu, Q., Lu, Q., Tao, Z., Wu, Q., Yin, W., Lu, J., and Pu, J. (2023). Protocol for Pyrotinib Cardiac Safety in Patients with HER2-Positive Early or Locally Advanced Breast Cancer\u2013The EARLY-MYO-BC Study. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1021937"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/s41416-020-0786-x","article-title":"Long-Term Cardiac Outcomes of Patients with HER2-Positive Breast Cancer Treated in the Adjuvant Lapatinib and\/or Trastuzumab Treatment Optimization Trial","volume":"122","author":"Eiger","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab Emtansine versus Capecitabine plus Lapatinib in Patients with Previously Treated HER2-Positive Advanced Breast Cancer (EMILIA): A Descriptive Analysis of Final Overall Survival Results from a Randomised, Open-Label, Phase 3 Trial","volume":"18","author":"Miles","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial Efficacy and Survival with Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer with Brain Metastases in the HER2CLIMB Trial","volume":"38","author":"Lin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11912-018-0708-8","article-title":"Tyrosine Kinase Inhibitor-Induced Hypertension","volume":"20","author":"Agarwal","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining Cardiovascular Toxicities of Cancer Therapies: An International Cardio-Oncology Society (IC-OS) Consensus Statement","volume":"43","author":"Herrmann","year":"2021","journal-title":"Eur. Heart J."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/833\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:16:54Z","timestamp":1780028214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":129,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ph19060833"],"URL":"https:\/\/doi.org\/10.3390\/ph19060833","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}